TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20369718
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment with the copper (II) compound)
Study: 17395047
Drug: Candesartan (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (titrated to 32 mg once per day)
Study: 15620485
Drug: Avanta implants
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Avanta implants
Study: 375958
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Atenolol and Chlorthalidone
Study: 375958
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy vs Placebo
Study: 29329168
Drug: MenABCWY booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenABCWY booster dose
Study: 24139668
Drug: Guided Experiential
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Experiential Learning (GEL)
Study: 6367882
Drug: Post-operative radiotherapy
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative radiotherapy (routine dose)
Study: 6367882
Drug: Higher dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dosage (more than 1510 ret)
Study: 6367882
Drug: Increased radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased radiotherapy dosage
Study: 30053018
Drug: CPE isolates
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPE isolates identified from rectal swabs
Study: 30053018
Drug: Carbapenemase characterization
Normalized name: Carbapenem
DrugBank: Carbapenem (DB18912)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbapenemase characterization and antibiotic susceptibility testing
Study: 21084546
Drug: Hydro Acoustic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydro Acoustic Therapy (HAT)
Study: 15805860
Drug: Control (ND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (ND before adjuvant therapy)
Study: 10756363
Drug: Aprotinin (pump-prime-only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (pump-prime-only dose)
Study: 10756363
Drug: No aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No aprotinin treatment (control)
Study: 31124600
Drug: Perioperative antibiotic
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative antibiotic prophylaxis (PAP)
Study: 31124600
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of PAP parenterally
Study: 29186175
Drug: Oral vocabulary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vocabulary training program (definition method)
Study: 29186175
Drug: Oral vocabulary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vocabulary training program (context method)
Study: 17723127
Drug: Nadroparin 2850
Normalized name: Nadroparine
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin 2850 antifactor Xa units once daily for 3 weeks
Study: 11719833
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose Bay 27‐9955 200 mg
Study: 11719833
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose Bay 27‐9955 70 mg
Study: 9604731
Drug: Piroxicam-FDDF (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam-FDDF (40 mg)
Study: 2882607
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium (550 mg)
Study: 2899196
Drug: NCDDP promotion
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NCDDP promotion of better treatment
Study: 20166432
Drug: Cefteram pivoxil
Normalized name: cefteram pivoxil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefteram pivoxil (test preparation)
Study: 20166432
Drug: Cefteram pivoxil
Normalized name: cefteram pivoxil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefteram pivoxil (reference preparation)
Study: 15585778
Drug: cis‐9,trans‐11 CLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: cis‐9,trans‐11 CLA (0.59, 1.19, and 2.38 g/d)
Study: 15585778
Drug: trans‐10,cis‐12 CLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: trans‐10,cis‐12 CLA (0.63, 1.26, and 2.52 g/d)
Study: 11745270
Drug: Protocol A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A: Twice-daily TBI (1.7 Gy for 3 days, total 10.2 Gy)
Study: 11745270
Drug: Protocol B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol B: Once-daily TBI (3 Gy for 4 days, total 12 Gy)
Study: 8238222
Drug: 5-fluorouracil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil (50 mg/ml for five minutes)
Study: 3608729
Drug: Sequential aspartate
Normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential aspartate aminotransferase measurement followed by CCA
Study: 28222649
Drug: Topical washing
Normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical washing with tranexamic acid
Study: 21816223
Drug: Broccoli sprouts
Normalized name: broccoli sprout extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli sprouts (40 g)
Study: 21816223
Drug: Broccoli supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli supplement (6 pills)
Study: 21816223
Drug: Placebo pills
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills (negative control)
Study: 17684633
Drug: Tetanus control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetanus control vaccine
Study: 12074614
Drug: Hyaluronidase injection
Normalized name: hyaluronidase Injection
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hyaluronidase injection and aspiration
Study: 9501748
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitor (SSRI), paroxetine, 20 mg/day
Study: 2244675
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation through the nose from a pressurized aerosol attached to a spacer device
Study: 666948
Drug: L(‐)‐bupivacaine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: L(‐)‐bupivacaine at 7.69 mmol/l
Study: 666948
Drug: D(+)‐bupivacaine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: D(+)‐bupivacaine at 7.69 mmol/l
Study: 666948
Drug: L(‐)‐bupivacaine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: L(‐)‐bupivacaine at 0.48 mmol/l
Study: 666948
Drug: L(‐)‐bupivacaine from
Approvals — FDA: no, EMA: no, PMDA: no
Description: L(‐)‐bupivacaine from 0.48‐3.84 mmol/l
Study: 666948
Drug: D(+)‐bupivacaine from
Approvals — FDA: no, EMA: no, PMDA: no
Description: D(+)‐bupivacaine from 0.48‐3.84 mmol/l
Study: 31023759
Drug: Amoxicillin-clavulanate (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate (80 mg/kg/day, maximum 980 mg of amoxicillin in two-divided doses) for 8 days
Study: 31023759
Drug: Placebo (equal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (equal volume and dosing frequency) for 8 days
Study: 28953325
Drug: Second-line protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line protease inhibitor (PI)-based ART
Study: 21508140
Drug: Anakinra 150
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra 150 mg sc once daily for 4 weeks
Study: 19080072
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg (Group 1, n=153)
Study: 19080072
Drug: Enalapril maleate
Normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril maleate and folic acid tablet at the ratio of 10/0.4 (Group 2, n=151)
Study: 19080072
Drug: Enalapril maleate
Normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril maleate and folic acid tablet at the ratio of 10/0.8 (Group 3, n=152)
Study: 16571963
Drug: Closed-loop propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Closed-loop propofol target control infusion
Study: 16571963
Drug: Manual propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual propofol target control infusion
Study: 12722174
Drug: Mirtazapine 45
Normalized name: mirtazapine 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine 45 mg per day for 2 weeks
Study: 12722174
Drug: Mirtazapine 45
Normalized name: mirtazapine 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine 45 mg per day
Study: 7939938
Drug: Chloroquine 300
Normalized name: chloroquine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 300 mg base weekly plus Fansidar 1 tab/week (group 3)
Study: 3521245
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (700,000 units)
Study: 24796043
Drug: Staging acupoint
Normalized name: fluorexon stain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staging acupoint embedment therapy, applied twice during the menstrual cycle (3 days before menstruation and during the 12th-14th days of menstruation) using specific acupoints.
Study: 24796043
Drug: Fenbid, 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenbid, 0.3 g orally, twice a day, starting 3 days before menstruation until pain relief, for 3 menstrual cycles.
Study: 24796043
Drug: Staging acupoint
Normalized name: fluorexon stain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staging acupoint embedment therapy
Study: 24490264
Drug: Oral high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral high-dose multivitamins and multiminerals
Study: 21649815
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bleaching agents (glycolic acid, kojic acid, lipohydroxyacid, and Vitreoscilla extract) applied daily for 3 months
Study: 18294022
Drug: Active transcranial
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active transcranial magnetic stimulation (TMS) administered 5 times per week at 10 pulses per second, at 120% of motor threshold, for a total of 3000 pulses/session.
Study: 17197740
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy (platinum-based)
Study: 9372379
Drug: Parenteral support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral support (isonitrogenous isocaloric)
Study: 1589282
Drug: Pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapy for acute spinal cord injury
Study: 10341115
Drug: Physostigmine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine administered orally every 2 hr, six times per day for 10 days
Study: 7745021
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist treatment (discontinued after 4 and 10 months)
Study: 1904090
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose and total parenteral nutrition with insulin
Study: 1904090
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous therapy alone
Study: 7440748
Drug: Child modulator
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child modulator intervention for a 6‐month period
Study: 30657228
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to a paediatric specialist for treatment planning
Study: 30657228
Drug: Restoration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restoration of cFPM including root canal treatment
Study: 27673579
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine (HD-Ara-C)
Study: 22289530
Drug: Remifentanil 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 6 ng/ml
Study: 22289530
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Remifentanil 0 ng/ml)
Study: 17132474
Drug: Transdermal oxybutynin
Normalized name: oxybutynin Transdermal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal oxybutynin for 6 months or less
Study: 9394816
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid (fluticasone propionate)
Study: 2446064
Drug: Ketanserin, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin, 10 mg i.v. or 40 mg t.i.d. orally
Study: 2446064
Drug: Ketanserin, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin, 10 mg i.v.
Study: 29961686
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) administered intravenously every 4 weeks (8 or 10 mg/kg based on weight) for 16 weeks, followed by random assignment to TCZ or placebo for 24 weeks.
Study: 25424567
Drug: Anodal tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodal tDCS (1 mA) for 20 minutes daily over two weeks
Study: 20051588
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg of 20% mannitol over 15 minutes
Study: 20051588
Drug: 1.0 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g/kg of 20% mannitol over 15 minutes
Study: 8908230
Drug: Intravenous adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous adrenaline (0.3 microgram/kg)
Study: 1914761
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily in the morning (N = 104)
Study: 1914761
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg once daily at night (N = 106)
Study: 30947606
Drug: Landmark-based corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landmark-based corticosteroid injection
Study: 24664349
Drug: 5.0 g
Normalized name: IODINE 5.0 g in 1 L TOPICAL SOLUTION [FS-104]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 g agave inulin
Study: 24664349
Drug: 7.5 g
Normalized name: glucose 15 GM per 37.5 GM Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 g agave inulin
Study: 24664349
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 g agave inulin)
Study: 23011957
Drug: Various dose
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various dose levels of the intervention
Study: 12557801
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin plus intravaginal misoprostol (n = 36)
Study: 12557801
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin plus placebo intravaginal (n = 34)
Study: 12557801
Drug: Intravaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal misoprostol plus intravenous placebo (n = 37)
Study: 9602955
Drug: Intravenous famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous famotidine pretreatment
Study: 27599225
Drug: Traditional in-office
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional in-office behavioral activation treatment for depression (BATD)
Study: 22094954
Drug: Valganciclovir prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir prophylaxis (2 × 450 mg oral valganciclovir/day for 100 days)
Study: 22094954
Drug: Preemptive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive therapy (monitored by CMV-PCR, 2 × 900 mg valganciclovir/day for at least 14 days after positive PCR)
Study: 18156412
Drug: 3 mg/d
Normalized name: Neupro 3 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/d zinc in a liquid supplement
Study: 18156412
Drug: 3 mg/d
Normalized name: Neupro 3 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/d zinc in a fortified porridge
Study: 7705376
Drug: Oral [13C]bicarbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral [13C]bicarbonate (0.1 mg kg‐1) at rest
Study: 7705376
Drug: Oral [13C]bicarbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral [13C]bicarbonate (0.1 mg kg‐1) during exercise
Study: 7705376
Drug: Oral [13C]bicarbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral [13C]bicarbonate (0.1 mg kg‐1) during recovery from exercise
Study: 7705376
Drug: Oral [13C]bicarbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral [13C]bicarbonate (0.1 mg kg‐1) at rest with induced acidosis
Study: 7705376
Drug: Oral [13C]bicarbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral [13C]bicarbonate (0.1 mg kg‐1) at rest with induced alkalosis
Study: 7705376
Drug: Oral [13C]bicarbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral [13C]bicarbonate (0.1 mg kg‐1) during acidosis
Study: 7705376
Drug: Oral [13C]bicarbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral [13C]bicarbonate (0.1 mg kg‐1) during alkalosis
Study: 3314521
Drug: Meclofenamate sodium,
Normalized name: Meclofenamate Sodium, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclofenamate sodium, 100 mg by mouth, three times a day
Study: 28735173
Drug: Detached mindfulness
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Detached mindfulness (DM; group treatment, twice weekly)
Study: 28735173
Drug: Leisure activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leisure activities (control condition, twice weekly)
Study: 26346941
Drug: NBI-98854 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBI-98854 (25 mg to 75 mg, once daily)
Study: 24093950
Drug: Accelerated initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Accelerated initiation of renal replacement therapy (within 12 hours of eligibility)
Study: 24093950
Drug: Standard initiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard initiation of renal replacement therapy (monitored over 7 days)
Study: 19636689
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg/d orally
Study: 3042939
Drug: Pancrease (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancrease (8 capsules daily)
Study: 3042939
Drug: Eurobiol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eurobiol (2 bottles daily)
Study: 31450908
Drug: Breast cancer
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast cancer screening adoption stages (pre-contemplation, contemplation, preparation, action, maintenance)
Study: 25171898
Drug: Probiotic yoghurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yoghurt plus probiotic capsules
Study: 25171898
Drug: Probiotic yoghurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yoghurt plus placebo capsules
Study: 25171898
Drug: Control milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control milk plus probiotic capsules
Study: 25171898
Drug: Control milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control milk plus placebo capsules
Study: 21150558
Drug: Boosted protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boosted protease inhibitors (any of the regimens including LPV/r)
Study: 21150558
Drug: Nonboosted protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonboosted protease inhibitors
Study: 21150558
Drug: Interruption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interruption of protease inhibitor regimens
Study: 18429758
Drug: Metformin (n=29)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (n=29)
Study: 18429758
Drug: Continual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continual treatment with Metformin for 12 months (n=30)
Study: 18429758
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment (Control group, n=12)
Study: 18429758
Drug: Patients never
Normalized name: Patent Blue
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients never treated with Metformin (n=8)
Study: 14640237
Drug: Candesartan (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (4 to 8 mg once-daily) added to ramipril (5 - 7.5 mg/day) for 16 weeks
Study: 14640237
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to ramipril (5 - 7.5 mg/day) for 16 weeks
Study: 8620276
Drug: Preoperative infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative infusion cholangiography (PIC)
Study: 6369522
Drug: Cimetidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1 g/day) + Intensive antacid treatment
Study: 6369522
Drug: Cimetidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1 g/day) + Placebo treatment
Study: 29775203
Drug: Optimal dynamic
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal dynamic treatment regime
Study: 29775203
Drug: Sequential, multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential, multiple assignment randomized clinical trial
Study: 12181246
Drug: Docetaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (100 mg/m²) followed by AC (60/600 mg/m²)
Study: 12181246
Drug: AC (60/600
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC (60/600 mg/m²) followed by Docetaxel (100 mg/m²)